Abcellera Biologics (ABCL) financial statements
Abcellera Biologics reported revenue of $75M in fiscal 2025, up 36.5% a year over 6 years.
Net income was -$146M and the operating margin -289.0%, against -35.5% in 2019.
Free cash flow was -$174M.
The diluted share count rose 97% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Abcellera Biologics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $12M | $233M | $375M | $485M | $38M | $29M | $75M |
| Research and development | $10M | $29M | $62M | $108M | $176M | $167M | $187M |
| Selling, general and admin | $4M | $16M | $49M | $67M | $89M | $98M | $83M |
| Operating income | -$4M | $156M | $204M | $217M | -$237M | -$315M | -$217M |
| Pre-tax income | -$2M | $158M | $219M | $239M | -$174M | -$200M | -$178M |
| Income tax | — | $39M | $66M | $81M | -$28M | -$38M | -$31M |
| Net income | -$2M | $119M | $153M | $159M | -$146M | -$163M | -$146M |
| EPS (diluted) | -$0.01 | $0.45 | $0.48 | $0.50 | -$0.51 | -$0.55 | -$0.49 |
| Diluted shares | 151M | 263M | 318M | 315M | 289M | 294M | 299M |
| Operating margin | -35.5% | 66.9% | 54.5% | 44.6% | -623.8% | -1091.7% | -289.0% |
| Net margin | -19.0% | 51.0% | 40.9% | 32.7% | -385.0% | -564.8% | -194.9% |
Balance sheet
Fiscal years, from Abcellera Biologics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | — | $594M | $476M | $387M | $761M | $626M | $534M |
| Receivables | — | $903,000 | — | — | $0 | $32M | $39M |
| Inventory | — | — | — | — | — | $0 | $6M |
| Total current assets | — | $813M | $930M | $1.0B | $872M | $751M | $728M |
| Property, plant and equipment | — | $18M | $112M | $217M | — | — | — |
| Goodwill | — | $32M | $48M | $48M | $48M | $48M | $48M |
| Total assets | — | $1.0B | $1.3B | $1.5B | $1.5B | $1.4B | $1.4B |
| Total current liabilities | — | $103M | $121M | $118M | $119M | $77M | $64M |
| Total liabilities | — | $175M | $293M | $308M | $336M | $304M | $390M |
| Shareholders' equity | $10M | $831M | $1.0B | $1.2B | $1.2B | $1.1B | $967M |
| Net debt | — | -$594M | -$476M | -$387M | -$133M | -$156M | -$129M |
Cash flow
Fiscal years, from Abcellera Biologics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $3M | $23M | $245M | $277M | -$44M | -$109M | -$131M |
| Capital spending | $4M | $10M | $58M | $71M | $77M | $78M | $43M |
| Free cash flow | -$1M | $13M | $186M | $207M | -$121M | -$187M | -$174M |
| Stock-based compensation | $890,000 | $8M | $31M | $49M | $64M | $68M | $56M |
| Net borrowing | $181,000 | -$5M | -$951,000 | — | — | — | — |
| Free cash flow margin | -11.2% | 5.6% | 49.6% | 42.6% | -317.7% | -648.4% | -231.7% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ABCL.
Open ABCL in InvestinglyQuestions
What was Abcellera Biologics's revenue in 2025?
$75M in fiscal 2025, from its 10-K filing.
How much free cash flow does Abcellera Biologics generate?
-$174M in fiscal 2025 (operating cash flow minus capital spending).
From Abcellera Biologics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.